Skip to main content

Table 2 Baseline clinical, laboratory and medication-related characteristics of the HIV-infected children on ART at Debre-Markos Referral Hospital, Northwest Ethiopia, from January 1, 2005 to March 31, 2019 (N = 408)

From: Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study

Characteristics

Categories

Frequency (N)

Percentage (%)

History of PMTCT

Yes

56

13.7

No

229

56.1

Not recorded

123

30.2

History of OIs

Yes

215

52.7

No

193

47.3

Weight for age

Normal

207

50.7

Underweight

201

49.3

Weight for height

Normal

311

76.2

Wasted

97

23.8

Height for age

Normal

197

48.3

Stunted

211

51.7

WHO clinical stage

Stage I and II

212

52.0

Stage III and IV

196

48.0

CD4 counts or %

Above the threshold

277

67.9

Below the thresheold

131

32.1

Hgb level

≥ 10 g/dl

366

89.7

<  10 g/dl

42

10.3

ART eligibility criteria

Test and treat

67

16.4

CD4 or WHO staging

341

83.6

Type of regimen at baseline

Nevirapine base

272

66.7

Efaveraze base

86

21.1

Protease inhibitor base

50

12.3

Ever taking IPT

Yes

217

53.2

No

191

46.8

ART adherence

Good

321

78.7

Fair/ poor

87

21.3

Past OI prophylaxis

Yes

248

60.8

No

160

39.2

ART side effect

Yes

19

4.7

No

389

95.3

Regimen change

Yes

84

20.6

No

324

79.4

Treatment failure

Yes

20

4.9

No

388

95.1

Functional status

Working

153

53.3

Ambulatory

113

39.4

Bed ridden

21

7.3

Developmental status

Appropriate

73

60.3

Delayed

41

33.9

Regressed

7

5.8

  1. PMTCT Prevention of Mother To Child Transmission, OIs Opportunistic Infections, WHO World Health Organization, Hgb Hemoglobin, CD4 Cluster of differentiation 4, and ART Antiretroviral Therapy